# Involvement of the GABAA receptor $\alpha$ subunit in the mode of action of etifoxine

César Mattei, Antoine Taly, Zineb Soualah, Ophélie Saulais, Daniel Henrion, Nathalie C. Guérineau, Marc Verleye, Christian Legros

▶ To cite this version:

César Mattei, Antoine Taly, Zineb Soualah, Ophélie Saulais, Daniel Henrion, et al.. Involvement of the GABAA receptor $\alpha$ subunit in the mode of action of etifoxine. Pharmacological Research, 2019, 145, pp.104250. 10.1016/j.phrs.2019.04.034 . hal-02344585

## HAL Id: hal-02344585
## https://hal.science/hal-02344585v1

Submitted on 4 Nov 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Involvement of the $GABA_A$ receptor α subunit in the mode of action of etifoxine

César Mattei[a*], Antoine Taly[b], Zineb Soualah[a], Ophélie Saulais[a], Daniel Henrion[a], Nathalie C. Guérineau[a,c], Marc Verleye[d] and Christian Legros[a*]

[a]*Institut MITOVASC, UMR CNRS 6015 - UMR INSERM U1083, Université d'Angers, 3 Rue Roger Amsler 49100 ANGERS, France*

[b]*Theoretical Biochemistry Laboratory, Institute of Physico-Chemical Biology, CNRS UPR9080, University of Paris Diderot Sorbonne Paris Cité, 75005 Paris, France*

[c]*present address: Institut de Génomique Fonctionnelle, CNRS UMR5203; INSERM U1191; Université Montpellier, 141 rue de la Cardonille, 34094 Montpellier CEDEX 05*

[d]*Biocodex, Department of Pharmacology, Zac de Mercières, 60200 Compiègne, France*

* Co-corresponding authors.

E-mail addresses: christian.legros@univ-angers.fr (C. Legros); cesar.mattei@univ-angers.fr (C. Mattei)

## ABSTRACT

Etifoxine (EFX) is a non-benzodiazepine psychoactive drug which exhibits anxiolytic effects through a dual mechanism, by directly binding to $GABA_A$ receptors ($GABA_A$Rs) and to the mitochondrial 18-kDa translocator protein, resulting in the potentiation of the GABAergic function. The β subunit subtype plays a key role in the EFX-$GABA_A$R interaction, however this does not explain the anxiolytic effects of this drug. Here, we combined behavioral and electrophysiological experiments to challenge the role of the $GABA_A$R α subunit in the EFX mode of action. After single administrations of anxiolytic doses (25-50 mg/kg, intraperitoneal), EFX did not induce any neurological nor locomotor impairments, unlike the benzodiazepine bromazepam (0.5-1 mg/kg, intraperitoneal). We established the EFX pharmacological profile on heteropentameric $GABA_A$Rs constructed with α1 to α6 subunit expressed in *Xenopus* oocyte. Unlike what is known for benzodiazepines, neither the γ nor δ subunits influenced EFX-mediated potentiation of GABA-evoked currents. EFX acted first as a partial agonist on α2β3γ2S, α3β3γ2S, α6β3γ2S and α6β3δ $GABA_A$Rs, but not on α1β3γ2S, α4β3γ2S, α4β3δ nor α5β3γ2S $GABA_A$Rs. Moreover, EFX exhibited much higher positive allosteric modulation towards α2β3γ2S, α3β3γ2S and α6β3γ2S than for α1β3γ2S, α4β3γ2S and α5β3γ2S $GABA_A$Rs. At 20 $\mu$M, corresponding to brain concentration at anxiolytic doses, EFX increased GABA potency to the highest extent for α3β3γ2S $GABA_A$Rs. We built a docking model of EFX on α3β3γ2S $GABA_A$Rs, which is consistent with a binding site located between α and β subunits in the extracellular domain. In conclusion, EFX preferentially potentiates α2β3γ2S and α3β3γ2S $GABA_A$Rs, which might support its advantageous anxiolytic/sedative balance.

**Chemical compounds studied in this article:** etifoxine (PubChem CID: 171544), bromazepam (PubChem CID: 2441), diazepam (PubChem CID: 3016)

47 **Keywords:** etifoxine; $GABA_A$ receptors; α subunit; anxiolysis; behavioral pharmacology; EFX-
48 binding mode
49
50
51 **Highlights**
52 • We investigated the influence of α subunits of $GABA_AR$ on the mode of action of etifoxine,
53 a non-benzodiazepine compound.
54 • Etifoxine induces anxiolysis without locomotion impairment and sedation in mice.
55 • Etifoxine strongly potentiates α3β3γ2S and moderately α2β3γ2S and α6β3γ2S $GABA_ARs$
56 compared to other $GABA_ARs$.
57 • A docking model of EFX with α3β3γ2S $GABA_AR$ reveals a binding site at the α/β interface,
58 close to the GABA-binding pocket.
59
60
61
62 **Abbreviations**
63 α(1-6)$GABA_ARs$, α1 to α6 subunit-containing $GABA_A$ receptors; BZD, benzodiazepine; BZP,
64 bromazepam; DZP, diazepam; EFX, etifoxine; $GABA_AR$, $GABA_A$ receptors; PAM, positive allosteric
65 modulator; TEVC, two-electrode voltage-clamp
66

## 1. Introduction

GABA$_A$Rs are heteropentameric membrane proteins that belong to the cys-loop ligand-gated ion channel superfamily [1]. They are permeant to chloride ions in response to GABA and decrease neuronal excitability through membrane hyperpolarization. To date, 19 mammalian GABA$_A$R subunits have been described and cloned (α1-6, β1-3, γ1-3, δ, ε, π, θ, ϱ1-3) [1]. The putative combination of these subunits provides a large heterogeneity of GABA$_A$Rs, with a stoichiometry of 2α, 2β and a complementary subunit (mainly γ or δ). The contribution of GABA$_A$Rs to fast or slow neuronal inhibition depends on their stoichiometry, their tissue distribution and their synaptic or extrasynaptic location. The most frequent assembly of synaptic receptors is α(1-3)β(1-3)γ(1-3), whereas extrasynaptic receptors dominantly contain α4 or α6 with β(1-3) and δ, or α5, β(1-3) and γ2 [1,2]. These differences in stoichiometry and distribution support their different neurophysiological functions and pharmacological properties [3,4].

GABA$_A$Rs are targeted by benzodiazepines (BZDs) and other drugs for the treatment of anxiety, epilepsy and sleep disorders [5,6]. BZDs act as positive allosteric modulators (PAMs) of GABA$_A$Rs by binding to a site at the interface between γ2 subunit and α subunits [7]. Classical BZDs, such as diazepam (DZP, Fig. 1), bromazepam (BZP, Fig. 1) and lorazepam, exhibit similar pharmacological profile in behavioral tests [8,9] and display poor selectivity over GABA$_A$Rs which contain α1, or α2 or α3 or α5 (α1GABA$_A$R, α2GABA$_A$R, α3GABA$_A$R, or α5GABA$_A$R) [10], which explains their undesirable effects, including withdrawal symptoms, sedation, amnesia, cognitive impairments and aggressiveness. Indeed, α1GABA$_A$Rs are associated with sedation, BZD addiction, anterograde amnesia, anticonvulsant activity and cortical plasticity [10-12]. α2GABA$_A$Rs and α3GABA$_A$Rs have been linked to anxiolysis, antihyperalgesia and myorelaxation [13-15]. α5GABA$_A$Rs are believed to be correlated to sedation, cognitive impairments and more recently, anxiolysis [14-17].

Etifoxine (2-ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1-benzoxazine hydrochloride, EFX, Fig. 1) is a non-BZD compound that exhibits anxiolytic and anticonvulsant effects in rodents [18] and is used for the treatment of anxiety-related disorders in humans [19,20]. EFX also displays anti-hyperalgesic and anti-inflammatory properties in different animal models [21,22]. Both *in vitro* and *in vivo* studies in rats suggested that the anxiolytic effects of EFX involve a dual mechanism of action, by directly binding to central $GABA_A$Rs and to the mitochondrial 18-kDa translocator protein (TSPO) with, as a result, potentiation of the GABAergic function [23,24]. Indeed, it has been shown that EFX activates TSPO through a direct binding and consecutively stimulates the synthesis of neurosteroids, such as, allopregnanolone, which act as PAMs of $GABA_A$Rs [25-27]. Although the affinity of EFX for $GABA_A$Rs was twice higher than the one for TSPO ($K_i$ of 6.1 $\mu$M vs $K_i$ of 12.7 $\mu$M), the predominance of one of the effect over the other, i.e. direct $GABA_A$Rs binding or through TSPO activation, in mediating its anxiolytic effect, is still debated [25,28,29].

The importance of the β subunit in the mode of action of EFX on $GABA_A$Rs has been clearly evidenced [24]. Constitutively-open homopentameric β$GABA_A$Rs are inhibited by EFX. In addition, α1$GABA_A$Rs and α2$GABA_A$Rs embedding β2 or β3 are more sensitive to EFX than α1$GABA_A$Rs and α2$GABA_A$Rs with β1. These data underline the importance of the β subunit in the EFX-$GABA_A$R interaction and for EFX-potentiation of GABA-induced currents of heteromeric $GABA_A$Rs. However, homopentameric β2$GABA_A$Rs are less sensitive to EFX than homopentameric β1$GABA_A$Rs [24], suggesting that the nature of the α subunit might also play a role in EFX-$GABA_A$Rs interaction. In addition, at anxiolytic doses, EFX has no sedative effects nor locomotion impairment in humans [19] or rodents [30] and this could hardly be explained by the equal potency of EFX on α2$GABA_A$R and α1$GABA_A$R since the latter is associated with sedation [10,12]. Thus, we hypothesized that the pharmacological profile of EFX reflects different sensitivities of all α subtypes containing-$GABA_A$Rs.

In this study, we first compared EFX and BZP in anxiolysis, sedation and locomotor impairment behavioral tests in acute conditions, in mice. The pharmacological effects of both EFX

116 and BZP already appear after a single administration [8,9,29,30]. Here, we determined the anxiolytic
117 doses of EFX and their possible influences on motor performance and arousal. We then assessed the
118 impact of α subunit isoforms on the effects of EFX on GABA-evoked currents. We characterized the
119 pharmacological profile of EFX on murine synaptic $GABA_A$Rs (α1β3γ2S, α2β3γ2S, α3β3γ2S,
120 α4β3γ2S and α6β3γ2S) and extrasynaptic $GABA_A$Rs (α5β3γ2S, α4β3δ and α6β3δ) using
121 electrophysiology. This pharmacological study was completed with a 3D model, showing the
122 interaction between EFX and $GABA_A$Rs. Our results demonstrate that the EFX mode of action
123 involves both α and β, but not γ or δ, subunits.
124

125 ## 2. Materials and methods

126 ### *2.1 Ethical statements*

127 All animal procedures were carried out in accordance with the European Community council
128 directive 2010/63/EU for the care and use of laboratory animals and were approved by our respective
129 local ethical committees (N°CEEA.45 and N°CEEA.72 for mice and N°CEEA.2012.68 for *Xenopus*,
130 https://www.ceea-paysdelaloire.com/) in addition to the French Ministry of Agriculture
131 (authorization N°B49071 and N° 02200.02). The NC3R's ARRIVE guidelines were followed in the
132 conduct and reporting of all experiments using animals.

133 ### *2.2 Animal care and conditioning*

134 Experiments were carried out using 7- to 9-week-old Balb/cByJ mice (25-30 g) purchased
135 from Charles River Laboratory (Les Oncins, France). Ten mice per translucent polypropylene cage
136 (internal dimensions in mm: 375 x 375 x 180, L x W x H) were housed under standard laboratory
137 conditions (22 ± 2° C, 12-h light/dark cycle, lights on at 7:00 AM) with food (AO4, SAFE, France)
138 and tap water available *ad libitum*. No less than one week of rest followed their arrival. Mice were
139 habituated to the testing room at least 60 min before performing any behavioral evaluation. All tests
140 occurred between 9:00 AM and 3:00 PM. The behavioral tests were performed by two well-trained
141 experimenters, who remained unaware of the administered treatment. In addition, all equipment was
142 wiped with 70% ethanol between animals to erase the olfactory stimuli. All experiments were
143 performed in a randomized manner. Single administrations of EFX (12.5-150 mg/kg, expressed as
144 hydrochloride salt) or BZP (0.25-1 mg/kg) were given by the intraperitoneal (IP) route, 30 min before
145 each test, except in the stress-induced hyperthermia test in which the compounds were administered
146 60 min before the test. Studies have shown that both compounds have a similar profile with plasma
147 peak at 15-30 min [25,31-33]. The control animals received an equivalent volume of vehicle (0.9%
148 NaCl, 1% tween 80 (v/v)). One male C57Bl/6N mouse was used for the cloning experiments. This

149 mouse had been included in a control group (not treated) from a previous protocol in which mice
150 were purchased from Janvier Labs (Le Genest-Saint-Isle, France). Euthanasia was performed using
151 $CO_2$ (3 ml/min, 4 min). Adult female *Xenopus laevis* were purchased from CRB (Rennes, France) and
152 had been bred in the laboratory in strict accordance with the recommendations of the Guide for the
153 Care and Use of Laboratory Animals of the European Community. Oocytes were harvested from
154 mature female *Xenopus laevis* frogs under 0.15% tricaine anaesthesia. All animals recovered after 2-
155 3 h. Every female is operated every three months, not less. A single female was used no more than 5
156 times.

157 *2. 3 Compounds*

158 EFX hydrochloride (batch 653, Biocodex, France), and BZP (batch 5788, Francochim,
159 France) (Fig. 1) were suspended in vehicle and administered (IP) in a volume of 10 ml/kg of body
160 weight. For electrophysiology, EFX and DZP (batch 105F0451, Sigma, France) were dissolved in
161 dimethylsulfoxide (DMSO) resulting in a maximal concentration of 0.1% DMSO, for oocyte
162 perfusion (control experiments were performed to demonstrate no effect of DMSO). All other
163 reagents and solvents were obtained from Sigma-Aldrich Merck (Saint-Louis, MO, USA) or Thermo
164 Fisher Scientific (Waltham, Massachusetts, USA).

165
166
167
168
169
170




171 **Fig. 1.** Structure of the positive allosteric modulators of $GABA_ARs$ used in this study. The 2D structure of EFX (PubChem
172 CID: 171544), DZP (PubChem CID: 3016) and BZP (PubChem CID: 2441) are illustrated.

173

174 *2.4 Anxiety-related behavioral assessment*

175 Stress-induced hyperthermia (SIH) is defined as the increase in body temperature observed
176 when a subject is exposed to an external stressor [34]. The day preceding the experiment, the animals
177 were isolated in smaller cages (dimensions: 265x160x140 mm). The body temperature (± 0.1°C) of
178 one singly housed mouse was measured twice via a rectal probe (YSI n°423; 2 mm diameter) coupled
179 to a thermometer (Letica-Temp812 model-Italia) at an interval of 10 min. The rectal temperature
180 measurement procedure (handling, insertion of the probe) constitutes the stressor. Drugs were injected
181 60 min before the first measurement (T1), followed by a second temperature measurement 10 min
182 later (T2). Methodological experiments have shown that the optimal conditions for drug testing are
183 found with an injection-test interval of 60 min or longer to avoid residual effects of the injection
184 procedure. Indeed, using a 60 min-injection-stress interval results in a hyperthermic response
185 comparable to animals that are not injected [35,36]. The reduction of SIH ($\Delta T$ = T2-T1) is considered
186 to reflect an anxiolytic-like effect [34-36]. Defensive burying after novel object exploration is a
187 behavior that can be elicited in rodents in response to aversive or new stimuli [37]. Mice were singly
188 housed in smaller cages (see above) with a sawdust depth of 2.5 cm the day before the test. Each
189 mouse was confronted with an unfamiliar object (4x4x6 cm; aluminium) introduced in the centre of
190 the cage. The time of contact or exploring the object (snout pointing toward the object at a distance
191 $<$ 1 cm with or without burying) was recorded for 10 min. The object was cleaned with alcohol (10%)
192 between each trial. This behavioral approach reveals an anxiety-like or fear state and its suppression
193 is associated with a reduction of the anxiety-like behavior [37].

194 *2.5 Spontaneous locomotor activity*

195 Testing was conducted in a quiet room under a light level of approximately 400 lux. The motor
196 activity cages (dimensions: 265x160x140 mm) were made of clear plastic and were changed between
197 each animal; these cages contained a minimum amount of sawdust. The locomotor activity was

198 measured by infra-red beam interruptions that were counted by a control unit (OptaVarimex,
199 Columbus, Ohio, USA). The sensitivity of this unit was set so that walking (horizontal activity) and
200 rearing (vertical activity) were measured. The beam breaks corresponding to spontaneous locomotor
201 activity were measured for 15 min.

202 *2.6 Rotarod performance*

203 The rotarod test assesses motor performance by measuring the capacity of mice to remain on
204 a 3-cm-diameter rod revolving 16 rpm (model 7600; Ugo Basile, Comerio, Italy). The mice were
205 trained to walk on the rotarod until they could complete three consecutive 120 s sessions without
206 falling off the rod. Twenty-four hours later, selected animals were treated with drugs before being
207 challenged. The rotarod performance time was measured three times, up to 120 s, and the mean was
208 adopted as the performance time for each animal.

209 *2.7 $GABA_AR$ subunit cDNA expression vectors*

210 pRK7 plasmids containing cDNAs encoding rat α2 subunits were a kind gift from Professor
211 Harmut Lüddens (University of Mainz, Mainz, Germany). The $GABA_AR$ α2 subunits from rat and
212 mouse are identical in amino acid sequence. pGW1 (=pRK5) plasmids containing cDNAs encoding
213 mouse β3 and γ2S subunits were kindly provided by Professor Steven J. Moss (Tufts University,
214 Boston, USA). The cDNAs encoding the α3, α4, α5, α6 and δ subunits used in this work were cloned
215 in mouse brain as described below.

216 *2.8 RNA extraction, RT-PCR and cloning of full-length cDNAs encoding α3-6 and δ subunits*

217 The brain was dissected from a male C57Bl/6N mouse for RNA extraction and purification.
218 Total RNA was then extracted using TRIzol® Reagent (Ozyme/Biogentex, France). First strand
219 cDNAs were synthesised from 5 $\mu$g of total RNA using SuperScriptTM III First-Strand Synthesis
220 System Super Mix (Invitrogen, USA) in the presence of oligo (dT)20, according to the manufacturer's

221 instructions. cDNAs encoding α3-6 and δ subunits were amplified using gene-specific primer pairs
222 encompassing each ORF (Supplemental Table 1) and high-fidelity thermostable DNA polymerase
223 (Advantage 2 Proofreading Polymerase kit, Clontech, Saint-Germain-en-Laye, France). cDNAs
224 fragments were purified with the Nucleospin PCR Cleanup Kit (Macherey-Nagel, Hoerdt, Germany)
225 and were subsequently cloned into PCR® 4 TOPO® (Invitrogen). Each clone was sequenced twice
226 on both strands using universal sense and reverse primers by GATC Biotech (Konstanz, Germany).
227 Sequence analyses were performed using BioEdit sequence analysis software. To transfer α3-6 and δ
228 subunits ORFs into the pRK5 expression vector, we adapted the ligase-free method for directional
229 cloning [38]. Plasmids and cDNA inserts were separately prepared by PCR using the proof reading
230 polymerase, KOD DNA polymerase (Merck Millipore, Fontenay sous Bois, France). To generate
231 sticky-end cDNAs, two individual PCR reactions were performed, PCR1 and PCR2, with gene-
232 specific primers containing short overhangs that allow annealing with the complementary overhangs
233 of the plasmid. pRK5 plasmid was modified to clone the $GABA_AR$ subunit ORFs flanked at their 5'
234 end by alfalfa mosaic virus (AMV) coat protein (RNA 4) and at their 3'end by 3′ -untranslated
235 regions (UTRs) from the Xenopus β-globin gene (3UTRXBG). The combination of both UTRs has
236 been shown to improve expression in both oocytes and mammalian cells [39]. First, a fusion of AMV
237 and 3'UTRXBG was constructed and cloned into pRK5 between EcoRI and XbaI. The resulting
238 modified vector (pRK5-5AMV-3UTRXBG) was used as a template for two individual PCRs with the
239 following pair primers: 5'-TAAACCAGCCTCAAGAACACCCGA-3' with 5'
240 GGTGGAAGTATTTGAAAGAAAATTAAAAATA-3' (PCR1), and 5'-
241 AAGCTTGATCTGGTTACCACTAAACC-3' with 5'-
242 AAAATTAAAAATAAAAACGAATTCAATCGATA-3' (PCR2). PCR1 and PCR2 products were
243 purified and mixed in T4 ligase buffer. To generate cDNA with sticky ends, the amplicons were
244 subjected to melting and reannealing, as previously described [38]. Inserts containing $GABA_AR$
245 subunit ORFs were also prepared in two individual PCRs (LIC-PCR1 and 2) with gene-specific

246 primer pairs (see Table S1 in supplementary data). Sticky-end inserts were obtained as described for
247 the plasmid preparations. For each construct, sticky-ends plasmid and $GABA_A$ cDNA preparation
248 were assembled in T4 ligase buffer and incubated for 2 h at 22°C. One to two microliters of this
249 assemblage were used to transform chemically competent E. coli cells (DG1, Eurogentec, Seraing,
250 Belgium). The resulting clones were sequenced as described above.

251 *2.9 Expression of $GABA_A$Rs in Xenopus oocytes*

252 Adult female *Xenopus laevis* (CRB, Rennes, France) were anaesthetized in ice-cold water
253 with 0.15% Tricaine (3-aminobenzoic acid ethyl ester, Sigma). Ovarian lobes were collected and
254 washed in standard oocyte saline (SOS containing 100 mM NaCl, 2 mM KCl, 1.8 mM $CaCl_2$, 1 mM
255 $MgCl_2$, 5 mM HEPES, pH 7.4). Stage V-VI oocytes were partially defolliculated by enzymatic
256 treatment with 2 mg/ml collagenase (type IA, Sigma) in $Ca^{2+}$-free SOS for 60 min. To express
257 functional $GABA_A$R, cDNA mixtures were directly injected into the nucleus (animal pole) of
258 individual defolliculated oocytes in different volumes of DNA solution at a concentration of 50 ng/$\mu$l
259 using a nanoinjector (Drummond Nanoject) (see Table S2 for receptor stoichiometry and DNA
260 quantity injected). Following injection, the oocytes were kept at 18°C in SOS supplemented with
261 gentamycin (50 µg/ml), penicillin (100 UI/ml), streptomycin (100 µg/ml), and sodium pyruvate
262 (2.5 mM). The incubation medium was replaced every two days. Oocytes were incubated 1 to 2 days
263 after DNA injection, depending on the $GABA_A$R subtype.

264 *2.10 Electrophysiological recordings*

265 Injected oocytes were tested for $GABA_A$R expression, at a holding potential of -60 mV using
266 a two-electrode voltage clamp amplifier (TEV-200, Dagan Corporation, Minneapolis, USA). Digidata
267 1440A interface (Axon CNS Molecular Devices, California, USA) and pCLAMP 10 software (Axon
268 CNS Molecular Devices) were used for acquisition. Cells were continuously superfused with standard
269 oocyte saline (SOS) at room temperature and were challenged with drugs in SOS. Electrodes were

270 filled with 1 M KCl / 2 M K acetate and had typical resistances of 0.5–2 MΩ in SOS. Drugs were
271 perfused at a flow rate close to ~4 ml/min. EFX and DZP were applied for 2 min before co-application
272 of GABA at $EC_{10}$, (determined for each $GABA_AR$ subtype, see Table S2 in supplementary data) until
273 the current response peaked. EFX was tested at concentrations ranging from 2 to 100 μM,
274 corresponding to its clinical use. Between the two applications, the oocytes were washed in SOS for
275 10-15 min to ensure full recovery from receptor desensitization (see Fig. 4A inbox). To control
276 whether GABA-evoked currents were mediated by ternary α1-6β3γ2S$GABA_A$Rs, control
277 experiments were performed using SOS containing 10 μM $Zn^{2+}$ to inhibit binary $GABA_A$Rs [40]. Data
278 were analysed using pCLAMP 10 software. Data are expressed as the mean ± SEM of 6-10 oocytes
279 generated from at least two collections. Concentration-effect relationships were analysed using the
280 following equation: $Y=Ymin + (Ymax-Ymin)/(1+10^{((LogEC50-X).nH)})$, where X is the concentration of EFX,
281 Ymin and Ymax are the minimum and highest responses, and nH is the Hill coefficient.

282 *2.11 Molecular model design*

283 The template chosen for homology modelling was the recently solved structure of a $GABA_AR$
284 (pdb code 4COF). The sequences of the human α2, β3 and γ2S $GABA_AR$ subunits were aligned with
285 those of the template (β3) using T-Coffee software [41]. The model was then prepared by homology
286 modeling using Modeler version 9.5 software [42] with default settings. One hundred models were
287 prepared, and the best model, according to the Discrete Optimized Protein Energy function (DOPE),
288 was selected. Side chains in the models were improved with Scwrl4 [43]. The whole model was then
289 improved with CHARMM [44,45]. Disulfide bridges formed between neighbouring cysteines both in
290 the 'Cys-loop' and between the M1 and M3 transmembrane helices in α and γ subunits, as recently
291 proposed [45]. The model was then subjected to minimization with decreasing harmonic potential.

292 *2.12 Docking*

293 The docking had been performed with AutoDock Vina [46]. The ligands and proteins were
294 prepared with prepare_ligand4.py and prepare_receptor4.py scripts, respectively. The side chains of
295 amino-acids in the binding site were made flexible (α3: Ser257 Ser258 and β3 Gln66, Tyr87, Gln89,
296 Tyr91). Each ligand was docked 100 times in a large cube of 30 Å in each dimension. Fig. 7 was
297 prepared with PyMOL (DeLano W.L. (2010) The PyMOL Molecular Graphics System, version 1.6,
298 Schrodinger, LLC, New York).

299 *2.13 Data analysis and statistics*

300 Data are presented as the mean ± SEM. Behavioral data were analysed by one-way ANOVA
301 followed by Dunnett's post-hoc test for comparison with the vehicle group. In cases in which the two
302 conditions (normality of the data and equality of variances) were not fulfilled, the non-parametric
303 Kruskal-Wallis procedure was used, followed by the post-hoc Dunn's test to evaluate the statistical
304 significance between the vehicle and treated groups. All test analyses were carried out by observers
305 who were blinded to the experimental procedures. Sample sizes (number of animals in the behavioral
306 studies) were not predetermined by a statistical method. Each behavioral experiment group included
307 at least 10 animals and this sample size needed to detect significant effects was based on experience
308 from previous studies. Significance tests between groups in the electrophysiological studies were
309 performed using variance analysis (one-way ANOVA) followed by Tukey's post-hoc test for
310 comparison of all groups or the non-parametric Mann and Whitney test when appropriate. Concerning
311 the electrophysiological experiments, we compiled data from different batches of oocytes and we
312 excluded data, in case of potential drift (> 0.6 mV) after pulling out the electrodes from the oocytes
313 and when current amplitudes were <10 nA or > 2 μA. GraphPad Prism 7.02 (GraphPad Software, San
314 Diego, USA) was used for all graphs and statistical analyses. Differences with $p<0.05$ were
315 considered significant (* for $p<0.05$, ** for $p<0.01$, *** for $p<0.001$, **** for $p<0.0001$).

316

317 **3. Results**

318 *3.1 Anxiolytic effects of EFX*

319 Previous studies have shown that EFX exhibits anxiolytic effects using conventional
320 behavioral tests such as elevated plus maze and dark-light box tests [33,47]. Here, we evaluated the
321 effect of EFX on stress and anxiety-related behaviors (stress-induced hyperthermia and novel object
322 exploration) to determine and confirm its anxiolytic doses in comparison with BZP. In non-treated
323 animals, handling stress resulted in a rise in body temperature close to 1°C (Fig. 2A to D). BZP
324 significantly lowered body temperature in animals at 1 mg/kg dose, before handling (T0) revealing
325 hypothermia ($H(3)=11.343$, $p=0.010$, then $p<0.05$, Dunn's test) (Fig. 2A). BZP dose-dependently
326 prevented stress-induced hyperthermia ($F_{3,41}=18.290$, $p<0.001$) (Fig. 2B). Compared to the vehicle-
327 treated animals, BZP was effective at doses of 0.5 and 1 mg/kg ($p<0.05$, Dunnett's test). EFX also
328 induced changes in body temperature but without hypothermia at the highest dose (50 mg/kg)
329 compared with control animals ($F_{3,41}=2.269$, $p=0.095$) (Fig. 2C). As observed for BZP, the
330 temperature increase was dose-dependently prevented by EFX ($H(3)=20.072$, $p<0.001$) with a
331 significant effect at 25 and 50 mg/kg dose ($p<0.05$, Dunn's test) (Fig. 2D). The anxiolytic effects of
332 BZP and EFX were also assessed by evaluating the behavioral approach in the presence of an
333 unfamiliar object. The duration of contact with a novel object was significantly decreased in animals
334 treated with BZP ($H(3)=15.304$, $p=0.002$) from the dose of 1 mg/kg ($p<0.05$, Dunn's test) (Fig. 2E).
335 The same was observed with EFX ($H(3)=17.536$, $p<0.001$), with a significant effect observed at doses
336 of 25 and 50 mg/kg compared with the control animals ($p<0.05$, Dunn's test) (Fig. 2F). In conclusion,
337 these two different behavioral tests led to similar anxiolytic doses of EFX (25-50 mg/kg, IP).

338

339

340




**Fig. 2.** Comparison of the effects of EFX and BZP on anxiety-related behaviors in mice. (A-D) The graphs show the evolution of the mean rectal temperature (± SEM) at T0 and T0+10 min after treatment with vehicle (dose 0) or BZP (A) or EFX (C) through IP route, 60 min before the first temperature measurement at T0. Histograms represent the mean (± SEM) of the difference of the rectal temperature measured at T0 and T+10 min in the same mouse after treatment with vehicle or BZP (B) or EFX (D) at the indicated doses. *p<0.05 compared with the vehicle group (Dunn test). (E,F) Histograms illustrate the mean time (± SEM) of contact with an unfamiliar object after IP administration of BZP (E) or EFX (F). *p<0.05 compared with the respective vehicle groups (dose 0). (see "data analysis and statistics" in the Material and Methods section). Animal numbers are indicated inside the bars.

*3.2 Motor performance assessment*

We then compared the impact of EFX and BZP on locomotion performance and motor coordination (Fig. 3). As illustrated in Fig. 3, BZP (IP route) decreased spontaneous locomotor activity ($H(3)=8.229$, $p=0.042$). These effects were statistically significant for the 1 mg/kg dose ($p<0.05$; Dunn's test) (Fig. 3A). EFX (IP route) decreased spontaneous locomotor activity with a significant difference at 100 mg/kg ($H(4)=9.633$, $p=0.047$) compared to control animals ($p<0.05$, Dunn's test) (Fig. 3B). BZP reduced the time on the rotarod ($H(3)=9.167$, $p=0.027$), with a significant effect at the 1 mg/kg dose ($p<0.05$, Dunn's test) (Fig. 3C). EFX was devoid of any effect up to the 100 mg/kg dose and affected motor coordination at the 150 mg/kg dose compared with control animals ($H(5)=19.006$, $p=0.002$ then $p<0.05$, Dunn's test) (Fig. 3D). In conclusion, BZP triggers motor impairments at anxiolytic doses (1 mg/kg, IP), while EFX exhibits no locomotor effects at efficient anxiolytic doses (25 to 50 mg/kg, IP).




382
383 **Fig. 3.** Comparison of BZP and EFX on locomotor activity and motor coordination. (A, B) Spontaneous locomotor
384 activities were assayed in the actimeter test in mice after IP injections of BZP (A) or EFX (B). The bars represent the
385 means ± SEM of the number of infrared beam interruptions over15 min. (C,D) Histograms illustrate the time on the rod
386 (mean ± SEM) after injection of BZP (C) or EFX (D). Animal numbers are indicated inside the bars. *p <0.05 compared
387 with the respective vehicle groups (see "data analysis and statistics" in the Material and Methods section).

388 ### *3.3 EFX effects on GABA currents depends on α subunit isoforms*

389 Because the distribution of $GABA_AR$ α subunits within the CNS is heterogeneous and
390 contributes to their receptor functions, we next investigated the involvement of α subunits in the EFX
391 mode of action using electrophysiology. To achieve this goal, we compared the effects of EFX (2 to
392 100 *μ*M) on GABA-induced currents elicited by α1$GABA_A$Rs, α2$GABA_A$Rs, α3$GABA_A$Rs,
393 α4$GABA_A$Rs, α5$GABA_A$Rs or α6$GABA_A$Rs, containing $\beta_3$ together with γ2S or δ, when appropriate.

394 We first challenged EFX effects on GABA-currents elicited by synaptic α1β3γ2S, α2β3γ2S
395 and α3β3γ2S $GABA_A$Rs expressed in *Xenopus* oocytes (Fig. 4). We observed that EFX displays both

396 agonist and potentiating effects as previously described [24]. The agonist effects of EFX were
397 revealed by its perfusion before co-application with GABA at $EC_{10}$ (Table S2). EFX exhibits almost
398 no agonist effects on α1β3γ2S $GABA_A$Rs (12.4 ± 5.8 and 23.7 ± 10.4 % of GABA $EC_{10}$ at 50 and 100
399 $\mu$M EFX, respectively) (Fig. 4A). In contrast, comparable agonist effects were observed with
400 α2β3γ2S $GABA_A$Rs (171 ± 24.9 % of GABA $EC_{10}$, at 100 $\mu$M EFX, Fig. 4B) and α3β3γ2S $GABA_A$Rs
401 (153.6 ± 27.3% of GABA $EC_{10}$, at 100 $\mu$M EFX, Fig. 4C). In comparison with GABA, EFX exerted
402 weaker agonist effects (~100 fold less efficient). For these three receptors, EFX potentiation of GABA
403 $EC_{10}$-evoked currents was dose-dependent, reaching a plateau at 50 $\mu$M (Fig. 4). At this concentration,
404 EFX induced a potentiation of GABA $EC_{10}$-evoked currents by 68.9 ± 11.6%, 160.3 ± 40.2% and
405 410.7 ± 20.2% of α1β3γ2S, α2β3γ2S and α3β3γ2S, respectively. The potentiating effects induced
406 by EFX from 2 to 100 $\mu$M, was ~2.4-6.0-fold stronger ($p<0.05$) with α3β3γ2S than with α1β3γ2S
407 and α2β3γ2S $GABA_A$Rs. Taking in account both agonist and potentiating effects, α1β3γ2S $GABA_A$Rs
408 are found much less sensitive to EFX than α2β3γ2S and α3β3γ2S $GABA_A$Rs.

**A**




**B**




**C**




409 **Fig. 4.** Effects of EFX on GABA-activated currents mediated by three synaptic $GABA_A$Rs (α1β3γ2S, α2β3γ2S and
410 α3β3γ2S). EFX effects were investigated by TEVC in *Xenopus* oocytes expressing α1β3γ2S (A), α2β3γ2S (B) and
411 α3β3γ2S $GABA_A$Rs (C). (A-C) Increasing concentrations of EFX (2, 20, 50 and 100 µM) were applied 2 min before co-
412 application of GABA at $EC_{10}$ (inbox). The amplitudes of EFX-evoked currents (●) were normalized to the amplitude of
413 control currents (■) obtained with GABA alone at $EC_{10}$. The potentiation effects of EFX was determined as the percentage
414 increase of $EC_{10}$-GABA current amplitudes (●). Left panel, GABA $EC_{10}$-induced representative currents are illustrated,
415 showing the partial agonist and positive modulatory effects of EFX. Right panel, data points (mean ± SEM of 6-11 oocytes
416 from at least two different animals) were fitted by non-linear regression to the Hill equation with variable slope using
417 GraphPad Prism 7. Statistical analyses were performed using one-way ANOVA tests followed by Tukey's post-hoc
418 correction (comparison with data obtained at 2 µM, *$p<0.05$, **$p<0.01$; ***$p<0.001$; ****$p<0.0001$, ns: not significant).

419 Based on pharmacokinetic data [30], we estimated that 20 $\mu$M matches the concentration of
420 free EFX in the mouse brain after injection of anxiolytic doses (25-50 mg/kg, Fig. 2). Thus, we
421 compared agonist and potentiating effects of 20 $\mu$M EFX on α(1-3) β3γ2S $GABA_A$Rs (Fig. 5A and
422 B). EFX (20 $\mu$M) acts as a partial agonist on α2$GABA_A$Rs and α3$GABA_A$Rs, while these agonist
423 effects are not significant on α1$GABA_A$Rs (Fig. 5A). As for the potentiating effects, α3$GABA_A$Rs
424 were much more sensitive to EFX (245.6 ± 41.8%) than α1 (50.1 ± 12.5%) and α2 (101.7 ± 12.2%
425 increase) -containing $GABA_A$Rs (Fig. 5B). In the synaptic cleft the GABA concentration rapidly rises
426 up to the millimolar range [48], we thus compared the GABA concentration-response relationships
427 in the presence and absence of 20 $\mu$M EFX at α1$GABA_A$Rs, α2$GABA_A$Rs and α3$GABA_A$Rs (Fig. 5C,
428 Table 1). EFX induced a decrease of GABA $EC_{50}$ with α1$GABA_A$Rs and α2$GABA_A$Rs in a similar
429 extent (~4-fold). In contrast, the GABA potency on α3$GABA_A$Rs was increased by 20.6 (Fig. 5C).
430 Taken together, our electrophysiological data show that, EFX behaves as a selective PAM of
431 α3$GABA_A$Rs at concentration equivalent to anxiolytic doses.

432




433 **Fig. 5.** Pharmacological profile of EFX over α(1-3)β3γ2S $GABA_ARs$. Comparison of EFX effects at 20 $\mu$M corresponding
434 to anxiolytic doses. Detailed analysis of agonist (A) and potentiating (B) effects of 20 $\mu$M EFX on α1β3γ2S, α2β3γ2S
435 and α3β3γ2S $GABA_ARs$. One-way ANOVA followed by Tukey post-hoc test was used for the analysis ((*p<0.05, **p
436 <0.01; ***p <0.001; ****p <0.0001). The number of recorded oocytes is indicated above or inside the bars. (C)
437 Concentration-response curves of GABA-evoked currents in the absence (open circles) and presence (close circles) of 20
438 $\mu$M EFX. Statistical analyses were performed using a non-parametric Mann & Whitney unpaired t-test. All data are
439 expressed as the mean ± SEM (n ≥ 6).

440 **Table 1**

441 Parameters of the GABA concentration-response relationship at α1β3γ2S, α2β3γ2S and α3β3γ2S
442 $GABA_ARs$ modulated by 20 $\mu$M EFX.

| | control | | + 20 µM EFX | |
|---|---|---|---|---|
| $GABA_AR$ subtype | $EC_{50}$ (µM) | nH | $EC_{50}$ (µM) | nH |
| α1β3γ2S | 9.99 ± 0.96 | 1.06 ± 0.09 | 2.37 ± 0.11 | 1.41 ± 0.08 |
| α2β3γ2S | 1.31 ± 0.12 | 1.69 ± 0.28 | 0.32 ± 0.03 | 1.14 ± 0.01 |
| α3β3γ2S | 10.89 ± 0.61 | 1.34 ± 0.09 | 0.53 ± 0.08 | 1.05 ± 0.15 |

443 The concentration-response relationships were analyzed using the Hill-Langmuir equation with variable slope. nH : Hill
444 slope. The data are mean ± SEM of at least two independent experiments.

445 Next, we tested EFX on synaptic α4β3γ2S $GABA_ARs$ and extrasynaptic α4β3δ $GABA_ARs$. In
446 both cases, EFX did not exhibit any agonist effects nor significantly potentiate GABA-induced
447 currents, even at high concentrations (Fig. 6A,B). Conversely, DZP at 2 μM enhanced GABA currents
448 elicited by α4β3γ2S $GABA_ARs$, as previously reported [49], but it did not affect α4β3δ $GABA_ARs$
449 (Fig. 6A,B). The extrasynaptic α5β3γ2S $GABA_ARs$ appeared to be also insensitive to EFX at low
450 concentrations (2 and 20 μM), and weakly sensitive to EFX at 50 μM (54.26 ± 29.19%) (Fig. 6C and
451 D). At 100 μM, EFX effects were significantly increased but did not reach a plateau (212.0 ± 31.97%).
452 The α6subunit was expressed with γ or δ in accordance with the native $GABA_AR$ composition in the
453 cerebellum [50]. Similar agonist effects were observed with α6β3γ2S $GABA_ARs$ (76.9 ± 20.3% of
454 GABA $EC_{10}$, at 100 μM EFX,) and α6β3δ $GABA_ARs$ (46.8 % of GABA $EC_{10}$, at 100 μM EFX) ($p=0.23$,
455 Mann and Whitney test) (Fig. 6E,F) as seen with α2$GABA_ARs$ and α3$GABA_ARs$ (Fig. 4B,C).
456 Moreover, the PAM effects of EFX revealed equal sensitivities of synaptic α6β3γ2S$GABA_ARs$ and
457 extrasynaptic α6β3δ $GABA_ARs$. EFX-potentiation of GABA-evoked currents reached a plateau at 50
458 μM EFX (170.5 ± 48.4% increase for α6β3γ2S $GABA_ARs$ and 143.6 ± 22.3% for α6β3δ $GABA_ARs$,
459 $p>0.99$, Mann and Whitney test) in accordance with a specific concentration-dependent mode of
460 action (Fig. 6E and F).

461




462 **Fig. 6.** Effects of EFX on GABA $EC_{10}$-activated currents mediated by synaptic (α4β3γ2S and α6 β3γ2S) and extrasynaptic
463 (α4β3δ, α5β3γ2S and α6β3δ) $GABA_AR$s. (A) Superimposed current traces evoked by GABA $EC_{10}$ in a representative cell
464 expressing α4β3γ2S or α4β3δ $GABA_AR$s in the absence (black traces) or presence of DZP (2 μM) or EFX. (B) Graphs
465 illustrating the mean (± SEM) EFX potentiation of GABA $EC_{10}$-activated currents mediated by synaptic and extrasynaptic
466 α4$GABA_AR$s. (C) Current traces evoked by GABA $EC_{10}$ in a representative oocyte expressing extrasynaptic α5β3γ2S
467 $GABA_AR$s in the absence (black trace) or presence of EFX (2 to 100 μM). (D) Graphs showing the mean (± SEM) EFX
468 potentiation of GABA $EC_{10}$-evoked currents. Statistical analyses were performed by one-way ANOVA followed by Tukey
469 post-hoc test (*p<0.05, **p <0.01; ***p <0.001; ****p <0.0001, ns: not significant). (E) Current traces evoked by GABA
470 $EC_{10}$ with synaptic α6β3γ2S and extrasynaptic α6β3δ $GABA_AR$s in the absence (black traces) or presence of increasing
471 concentrations of EFX (2 to 100 μM). (F) Graphs showing the mean (± SEM) EFX potentiation of GABA $EC_{10}$-activated
472 currents mediated by α6β3γ2S and α6β3δ $GABA_AR$s. Statistical analyses were performed using a non-parametric Mann
473 & Whitney unpaired t-test (* p<0.05; ns: not significant).

474 In conclusion, taking into account both agonist and potentiating EFX effects, $GABA_ARs$ can
475 be ranked in three categories: i) resistant ($\alpha$4$GABA_ARs$ and $\alpha$5$GABA_ARs$), ii) moderately sensitive
476 ($\alpha$1$GABA_ARs$, $\alpha$2$GABA_ARs$ and $\alpha$6$GABA_ARs$) and iii) highly sensitive ($\alpha$3$GABA_ARs$) to EFX.

477 *3.7 Modelling of EFX-$\alpha3\beta3\gamma2_S GABA_AR$ interaction*

478 To gain further insight into the mechanism of action of EFX, we generated a homology model
479 of $\alpha3\beta3\gamma2_S$ $GABA_AR$ (Fig. 7A) to predict how EFX binds to its receptor site. The resulting computed
480 docking model was consistent with an EFX binding site located between $\alpha$ and $\beta$ subunits in the
481 extracellular domain (Fig. 7B and C). The pocket found at the interface between $\alpha$3 and $\beta$3 subunits,
482 homologous to the GABA binding sites, was large enough to accommodate EFX. Among the putative
483 binding modes, one was found in which EFX bound in the proximity of five amino acid residues of
484 the $\beta$3 subunit: N66, Y87, Q89, Y91 and R194 (Fig. 7D). In $\alpha$3 subunit, we identified two amino acid
485 residues (S257, S258) that may be involved in the EFX-$GABA_AR$ interaction. Two residues of $\beta$3,
486 N66 and R194, are conserved in $\beta$2 and $\beta$3 and are different in $\beta$1 subunits (R66 and N194). This pair
487 of amino acids might therefore control the binding mode of EFX as variations at these residues might
488 explain the subunit selectivity.

489




490 **Fig. 7.** Binding modes of EFX obtained by docking on the mouse $\alpha_3\beta_3\gamma_{2S}$ $GABA_AR$. (A) Model of the receptor viewed
491 from the membrane plane. The protein is shown in cartoon representation with a different color code for each polypeptide.
492 The position of the membrane is represented by a sphere positioned at the level of lipid head groups as determined by the
493 Orientations of Proteins in Membranes database [51]. (B-D) Binding mode of EFX by docking on the mouse
494 $\alpha_3\beta_3\gamma_{2S}GABA_AR$ model. EFX (CPK representation) interacts with a pocket localized at the $\alpha_3$ (cyan) $\beta_3$ (magenta)
495 interface, homologous to GABA binding sites. The binding sites of BZD, GABA and EFX are indicated by arrows (B).
496 Lateral view of the extracellular domain (C). Close-up showing the EFX-binding pocket (EFX appears in sticks) (D).

497 ## 4. Discussion

498 The current study shows that a single administration EFX (25-50 mg/kg) induced a robust
499 anxiolytic behavior in mice subjected to stress-induced hyperthermia and novel object exploration
500 tests. In the same range of doses, and unlike classical BZDs, EFX did not evoke any secondary effects
501 in the spontaneous locomotor activity and rotarod performance. Pharmacokinetic data in Balb/cByJ
502 mice treated with anxiolytic doses indicated that EFX brain content reaches concentration range from
503 16 to 31 $\mu$M [30]. In addition, EFX exhibits lipophilic properties with an estimated partition
504 coefficient (log P) of 2 and a brain/ plasma ratio range of 2.2-2.9 [52]. Based on different reports in
505 the literature, it is reasonable to assume that an equilibrium between the total and free fractions which
506 depends on physicochemical properties of the compound occurs in the brain tissue [53-55] and, as a
507 result this could support the relevance of the effective concentrations in the present
508 electrophysiological studies. In this context, we demonstrated that the α subunit plays an important
509 role in EFX-induced positive effects on $GABA_A$Rs. EFX favours GABA potency over $GABA_A$Rs with
510 the following rank order: α3β3γ2S > α2β3γ2S > α6β3γ2S and no or weak effects on α1β3γ2S,
511 α4β3γ2S and α5β3γ2S.

512 ### *4.1 EFX displays anxiolytic properties with weak side effects*

513 Our findings confirm the anxiolytic properties of EFX at similar doses to those previously
514 used in other anxiety mouse models [30]. In comparison, EFX displays approximately 50-fold less
515 potent anxiolytic effects than BZP and DZP [8,9]. However, both BZP and DZP strongly alter
516 locomotor performance and awakening at anxiolytic doses, while EFX does not. It is noteworthy that
517 pharmacokinetic factors involving, for example, active metabolites or differences in the extent of
518 metabolism could explain the differences in the effective doses of EFX and BZP. We reasoned that
519 BZDs, which have a high potency (submicromolar) for enhancing GABA-evoked currents, will
520 produce effects at a lower concentration than EFX which has a lower potency (micromolar) for

GABA$_A$Rs. Interestingly, EFX exhibits higher efficacy for α2GABA$_A$Rs and α3GABA$_A$Rs, known to mediate anxiolytic effects (up to 171% and 410% for α2GABA$_A$Rs and α3GABA$_A$Rs, respectively) than DZP (108% and 160% for α2GABA$_A$Rs and α3GABA$_A$Rs, respectively) [56].

Compelling evidence indicates that the anxiolytic effects of BZP cannot be dissociated from its sedative and myorelaxant effects, while the therapeutic margin is wider with EFX. In addition, previous results have shown that EFX is devoid of amnesic effects at anxiolytic doses (50 mg/kg, IP route) in the rat [57]. On the other hand, BZP and DZP display amnesic activity at doses producing anxiolytic effects (from 0.25mg/kg, IP) in the mouse [58]. As observed in rodents, patients treated with EFX for adjustment disorders with anxiety do not exhibit adverse effects, such as the memory and vigilance disturbances [19,59,60]. This is perfectly in line with our electrophysiological data showing the absence of effects of EFX on α4GABA$_A$Rs and α5GABA$_A$Rs, known to be involved in cognitive functions [4].

We cannot rule out the possibility that EFX anxiolytic properties rely on both direct and indirect GABA$_A$R stimulation mechanisms. Since EFX has been shown to stimulate the synthesis of neurosteroids, such as allopregnenolone, which directly boosts GABA$_A$R activity [27,43,61], this may account for its anxiolytic effects. Neurosteroids equally enhance GABA-evoked currents mediated by α1GABA$_A$Rs, α3GABA$_A$Rs and α6GABA$_A$Rs, while they have little effects on α2GABA$_A$Rs, α4GABA$_A$Rs and α5GABA$_A$Rs [58,62], suggesting that EFX should induce both sedation and anxiolysis. However, because EFX did not induce sedation at anxiolytic doses, this minors the involvement of neurosteroids in the EFX mode of action. We hypothesize that EFX may exert its anxiolytic effect through a direct enhancement of the activity of GABA$_A$Rs. To date, there is no experimental data on EFX modulation of GABA$_A$Rs to conclude a plausible mode of action. However, using recombinant murine GABA$_A$Rs expressed in *Xenopus* oocytes, it has been shown that both efficacy and potency of GABA are enhanced by EFX [24]. The effect of EFX might be explained by

545 either mechanism, i.e. an increased frequency of the open state of $GABA_A$Rs and/or an increase of the
546 duration of burst openings.

547 Further studies using a chronic treatment are warranted to support the specificity of EFX
548 compared to BZDs in the development of tolerance complex phenomenom involving in part selective
549 alterations in $GABA_A$R receptor subunit expression [63].

550 *4.2 The EFX mode of action depends on the $GABA_A$R α subunits*

551 Our electrophysiological data demonstrate that EFX behaves both as a partial agonist and a
552 PAM of $GABA_A$Rs. In fact, EFX strongly potentiates GABA-evoked currents mediated by
553 α2$GABA_A$Rs, α3$GABA_A$Rs and/or α6$GABA_A$Rs, with major effects on α3$GABA_A$Rs in comparison to
554 any other $GABA_A$Rs. This was also highlighted by a larger enhancement of the GABA potency on
555 α3$GABA_A$Rs, than on α1$GABA_A$Rs and α2$GABA_A$Rs. However, the involvement of α3$GABA_A$Rs in
556 anxiolysis is still a matter of debate. As mentioned above, there is still a controversy concerning the
557 implication of α2$GABA_A$Rs, α3$GABA_A$Rs and α5$GABA_A$Rs in the control of anxiety-related
558 behaviors [14,15,17,64]. Other non-BZD compounds such as TPA023, AZD6280 and AZD7325,
559 have been shown to exert anxiolysis without sedative side effects in rodents and/or humans by
560 preferentially enhancing α2$GABA_A$Rs and α3$GABA_A$Rs over the other $GABA_A$R subtypes [64,65].
561 However, these three compounds bind to the BZD site, while EFX does not [23]. In addition, another
562 non-BZD compound, TP003 was first reported as a selective PAM of α3$GABA_A$R, and initially
563 considered to exhibit anxiolytic properties through this receptor [14,66]. However, two recent studies
564 have revealed that this drug is not selective to α3$GABA_A$R, but equally modulates GABA-evoked
565 currents mediated by α5$GABA_A$R and also moderately potentiates α1$GABA_A$Rs and α2$GABA_A$R
566 [65,67]. TP003 was indeed shown to counteract anxiety behaviors in both rodents and squirrel
567 monkeys and thus highlights the medical use of α3$GABA_A$R-selective molecules as efficient

568 anxiolytics with no sedative secondary effects [14,66]. Therefore, we believe that the anxiolytic-like
569 effects of EFX in mice are related to the modulation of α2GABA$_A$Rs and α3GABA$_A$Rs.

570 *4.3 The EFX binding site*

571 Our objective was to challenge the possible influence of the α subunit for at least three reasons.
572 First, $β_2$ homopentamers are less sensitive to EFX than β3 homopentamers. However, when they are
573 combined with α1 or α2 subunits, the resulting binary GABA$_A$Rs display a different pharmacological
574 profile: α1β2-3 and α2β2-3 GABA$_A$Rs are equally potentiated, indicating that α1 and α2 subunits
575 modulate EFX potentiation [24]. Second, α1 and α2 subunits share a high amino acid sequence
576 identity, while α4-6 are structurally more distant [68] and thus could potentially have distinct
577 pharmacological influences. Here, we bring compelling evidences demonstrating that stimulating
578 effects of EFX are much stronger on α3β3γ2S than on α2β3γ2S, α6β3γ2S and α1β3γ2S GABA$_A$Rs,
579 while α4β3γ2S and α5β3γ2S are almost insensitive. Altogether, our findings indicate a strong
580 regulatory effect of the α subunit on EFX mode of action.

581 We also examined the involvement of γ2S and δ subunits in the mode of action of EFX and
582 we observed that α4β3γ2S and α4β3δ on one hand, α6β3γ2S and α6β3δ GABA$_A$Rs on the other hand,
583 are equally sensitive to EFX. This reinforces the idea that, unlike BZDs [7], the third subunit is not
584 involved in the EFX-GABA$_A$R interaction.

585 Consecutively, we hypothesized that EFX site is likely located between the α and β subunits.
586 Our 3D docking simulation suggests that EFX binds in a pocket at the α/β subunit interface
587 homologous to the GABA binding pocket recently described [69], highlighting putative amino acid
588 residues involved in EFX binding. Interestingly, among them, two residues of $β_3$, N66 and R194, are
589 conserved in $β_2$ and $β_3$ and differ in the $β_1$ subunits (R66 and N194). This pair of amino acids may
590 belong to the binding site of EFX and summarise its subunit selectivity. Site-directed mutagenesis
591 experiments are required to validate this hypothesis and to define the residues underlying the EFX

592 selectivity towards α3GABA$_A$Rs. These experiments will allow us to construct genetic models in
593 which specific α(1-6)GABA$_A$Rs subtypes will be rendered insensitive to EFX to directly correlate
594 specific α2GABA$_A$Rs or α3GABA$_A$Rs to its anxiolytic effects or test whether α3GABA$_A$R functions
595 are involved in the regulation of anxiety.

596 ## 5. Conclusions

597 In conclusion, this study provides new information about the mode of action of EFX, a non-
598 BZD anxiolytic compound, showing that it potentiates GABA transmission, mainly through the
599 interaction with α2GABA$_A$Rs and α3GABA$_A$Rs and likely their associated functions. Modelling
600 simulation indicates that EFX could interact with a pocket localized at the α/β subunits
601 interface,homologous to the GABA binding site. To the best of our knowledge, EFX belongs to the
602 group of non-BZD molecules which act at a site distinct from the classical BZDs site and exert
603 positive effects on anxiety without secondary effects. EFX may therefore serve as a molecular
604 template for the design of novel anxiolytics with similar mechanisms of action and higher potency.

605

606 **Conflict of interest**

607 The authors declare no conflicts of interest.

608

609 **Acknowledgements**

610 We are indebted to Dr. Alain Hamon and Bastien Faucard for helpful discussions about the work. We
611 are grateful to Sophie Quinchard for technical assistance. We also thank Dr. Ulrich Jarry, Charlène
612 Labège, Céline Alamichel and Vincent Juif for their contribution to preparing the cDNAs encoding
613 α3-6 subunits in the pRK5 vector and electrophysiology experiments.

614

## References

[1] R.W. Olsen, W. Sieghart, International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update, Pharmacol Rev 60(3) (2008) 243-60.

[2] M. Farrant, Z. Nusser, Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors, Nat Rev Neurosci 6(3) (2005) 215-29.

[3] R.W. Olsen, W. Sieghart, GABA A receptors: subtypes provide diversity of function and pharmacology, Neuropharmacology 56(1) (2009) 141-8.

[4] E. Engin, R.S. Benham, U. Rudolph, An Emerging Circuit Pharmacology of GABAA Receptors, Trends Pharmacol Sci 39(8) (2018) 710-732.

[5] T. Atkin, S. Comai, G. Gobbi, Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery, Pharmacol Rev 70(2) (2018) 197-245.

[6] M.J. Brodie, F. Besag, A.B. Ettinger, M. Mula, G. Gobbi, S. Comai, A.P. Aldenkamp, B.J. Steinhoff, Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review, Pharmacol Rev 68(3) (2016) 563-602.

[7] D.B. Pritchett, H. Sontheimer, B.D. Shivers, S. Ymer, H. Kettenmann, P.R. Schofield, P.H. Seeburg, Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology, Nature 338(6216) (1989) 582-5.

[8] L. Steru, B. Thierry, R. Chermat, B. Millet, P. Simon, R.D. Porsolt, Comparing benzodiazepines using the staircase test in mice, Psychopharmacology (Berl) 92(1) (1987) 106-9.

[9] M. Bourin, M. Hascoet, B. Mansouri, M.C. Colombel, J. Bradwejn, Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models, J Psychiatry Neurosci 17(2) (1992) 72-7.

[10] U. Rudolph, F. Knoflach, Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes, Nat Rev Drug Discov 10(9) (2011) 685-97.

[11] U. Rudolph, F. Crestani, D. Benke, I. Brunig, J.A. Benson, J.M. Fritschy, J.R. Martin, H. Bluethmann, H. Mohler, Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes, Nature 401(6755) (1999) 796-800.

[12] R.M. McKernan, T.W. Rosahl, D.S. Reynolds, C. Sur, K.A. Wafford, J.R. Atack, S. Farrar, J. Myers, G. Cook, P. Ferris, L. Garrett, L. Bristow, G. Marshall, A. Macaulay, N. Brown, O. Howell, K.W. Moore, R.W. Carling, L.J. Street, J.L. Castro, C.I. Ragan, G.R. Dawson, P.J. Whiting, Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype, Nat Neurosci 3(6) (2000) 587-92.

648 [13] K. Löwe, F. Crestani, R. Keist, D. Benke, I. Brunig, J.A. Benson, J.M. Fritschy, T. Rulicke, H.
649 Bluethmann, H. Mohler, U. Rudolph, Molecular and neuronal substrate for the selective attenuation
650 of anxiety, Science 290(5489) (2000) 131-4.
651 [14] R. Dias, W.F. Sheppard, R.L. Fradley, E.M. Garrett, J.L. Stanley, S.J. Tye, S. Goodacre, R.J.
652 Lincoln, S.M. Cook, R. Conley, D. Hallett, A.C. Humphries, S.A. Thompson, K.A. Wafford, L.J.
653 Street, J.L. Castro, P.J. Whiting, T.W. Rosahl, J.R. Atack, R.M. McKernan, G.R. Dawson, D.S.
654 Reynolds, Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the
655 anxiolytic effects of benzodiazepines, J Neurosci 25(46) (2005) 10682-8.
656 [15] J.R. Atack, GABAA receptor alpha2/alpha3 subtype-selective modulators as potential
657 nonsedating anxiolytics, Curr Top Behav Neurosci 2 (2010) 331-60.
658 [16] M.M. Savic, S. Huang, R. Furtmuller, T. Clayton, S. Huck, D.I. Obradovic, N.D. Ugresic, W.
659 Sieghart, D.R. Bokonjic, J.M. Cook, Are GABAA receptors containing alpha5 subunits contributing
660 to the sedative properties of benzodiazepine site agonists?, Neuropsychopharmacology 33(2) (2008)
661 332-9.
662 [17] L.M. Behlke, R.A. Foster, J. Liu, D. Benke, R.S. Benham, A.J. Nathanson, B.K. Yee, H.U.
663 Zeilhofer, E. Engin, U. Rudolph, A Pharmacogenetic 'Restriction-of-Function' Approach Reveals
664 Evidence for Anxiolytic-Like Actions Mediated by alpha5-Containing GABAA Receptors in Mice,
665 Neuropsychopharmacology 41(10) (2016) 2492-501.
666 [18] J.R. Boissier, P. Simon, M. Zaczinska, J. Fichelle, [Experimental psychopharmacologic study
667 of a new psychotropic drug, 2-ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1-benzoxazine],
668 Therapie 27(2) (1972) 325-38.
669 [19] N. Nguyen, E. Fakra, V. Pradel, E. Jouve, C. Alquier, M.E. Le Guern, J. Micallef, O. Blin,
670 Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with
671 adjustment disorders with anxiety: a double-blind controlled study in general practice, Hum
672 Psychopharmacol 21(3) (2006) 139-49.
673 [20] D.J. Stein, Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a
674 randomized controlled trial, Adv Ther 32(1) (2015) 57-68.
675 [21] M. Aouad, N. Petit-Demouliere, Y. Goumon, P. Poisbeau, Etifoxine stimulates
676 allopregnanolone synthesis in the spinal cord to produce analgesia in experimental
677 mononeuropathy, Eur J Pain 18(2) (2014) 258-68.
678 [22] E. Simon-O'Brien, D. Gauthier, V. Riban, M. Verleye, Etifoxine improves sensorimotor deficits
679 and reduces glial activation, neuronal degeneration, and neuroinflammation in a rat model of
680 traumatic brain injury, J Neuroinflammation 13(1) (2016) 203.

681 [23] R. Schlichter, V. Rybalchenko, P. Poisbeau, M. Verleye, J. Gillardin, Modulation of
682 GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine,
683 Neuropharmacology 39(9) (2000) 1523-35.
684 [24] A. Hamon, A. Morel, B. Hue, M. Verleye, J.M. Gillardin, The modulatory effects of the
685 anxiolytic etifoxine on GABA(A) receptors are mediated by the beta subunit, Neuropharmacology
686 45(3) (2003) 293-303.
687 [25] M. Verleye, Y. Akwa, P. Liere, N. Ladurelle, A. Pianos, B. Eychenne, M. Schumacher, J.M.
688 Gillardin, The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases
689 the neurosteroid levels in rat brain, Pharmacol Biochem Behav 82(4) (2005) 712-20.
690 [26] B. Costa, C. Cavallini, E. Da Pozzo, S. Taliani, F. Da Settimo, C. Martini, The Anxiolytic
691 Etifoxine Binds to TSPO Ro5-4864 Binding Site with Long Residence Time Showing a High
692 Neurosteroidogenic Activity, ACS Chem Neurosci 8(7) (2017) 1448-1454.
693 [27] P. Liere, A. Pianos, J.P. Oudinet, M. Schumacher, Y. Akwa, Differential effects of the 18-kDa
694 translocator protein (TSPO) ligand etifoxine on steroidogenesis in rat brain, plasma and
695 steroidogenic glands: Pharmacodynamic studies, Psychoneuroendocrinology 83 (2017) 122-134.
696 [28] M. Verleye, R. Schlichter, J.M. Gillardin, Interactions of etifoxine with the chloride channel
697 coupled to the GABA(A) receptor complex, Neuroreport 10(15) (1999) 3207-10.
698 [29] M. Verleye, I. Heulard, J.M. Gillardin, Investigation of the anticonvulsive effect of acute
699 immobilization stress in anxious Balb/cByJ mice using GABA A-related mechanistic probes,
700 Psychopharmacology (Berl) 197(4) (2008) 523-34.
701 [30] M. Verleye, I. Heulard, P. Nuss, J.M. Gillardin, Effects of stress and etifoxine on pentobarbital-
702 induced loss of righting reflex in Balb/cByJ and C57BL/6J mice, Neurosci Lett 353(2) (2003) 127-
703 30.
704 [31] M. Sansone, Benzodiazepines and amphetamine on avoidance behaviour in mice, Arch Int
705 Pharmacodyn Ther 218(1) (1975) 125-32.
706 [32] R.B. Rastogi, Y.D. Lapierre, R.L. Singhal, Effect of a new benzodiazepine bromazepam on
707 locomotor performance and brain monoamine metabolism, J Neural Transm 42(4) (1978) 251-61.
708 [33] M. Verleye, S. Dumas, I. Heulard, N. Krafft, J.M. Gillardin, Differential effects of etifoxine on
709 anxiety-like behaviour and convulsions in BALB/cByJ and C57BL/6J mice: any relation to
710 overexpression of central GABAA receptor beta2 subunits?, Eur Neuropsychopharmacol 21(6)
711 (2011) 457-70.
712 [34] B. Olivier, T. Zethof, T. Pattij, M. van Boogaert, R. van Oorschot, C. Leahy, R. Oosting, A.
713 Bouwknecht, J. Veening, J. van der Gugten, L. Groenink, Stress-induced hyperthermia and anxiety:
714 pharmacological validation, Eur J Pharmacol 463(1-3) (2003) 117-32.

715 [35] T.J. Zethof, J.A. Van der Heyden, J.T. Tolboom, B. Olivier, Stress-induced hyperthermia in
716 mice: a methodological study, Physiol Behav 55(1) (1994) 109-15.
717 [36] J.A. Van der Heyden, T.J. Zethof, B. Olivier, Stress-induced hyperthermia in singly housed
718 mice, Physiol Behav 62(3) (1997) 463-70.
719 [37] S.F. De Boer, J.M. Koolhaas, Defensive burying in rodents: ethology, neurobiology and
720 psychopharmacology, Eur J Pharmacol 463(1-3) (2003) 145-61.
721 [38] A. Walker, J. Taylor, D. Rowe, D. Summers, A method for generating sticky-end PCR products
722 which facilitates unidirectional cloning and the one-step assembly of complex DNA constructs,
723 Plasmid 59(3) (2008) 155-62.
724 [39] S.P. Venkatachalan, J.D. Bushman, J.L. Mercado, F. Sancar, K.R. Christopherson, A.J. Boileau,
725 Optimized expression vector for ion channel studies in Xenopus oocytes and mammalian cells using
726 alfalfa mosaic virus, Pflugers Arch 454(1) (2007) 155-63.
727 [40] A. Draguhn, T.A. Verdorn, M. Ewert, P.H. Seeburg, B. Sakmann, Functional and molecular
728 distinction between recombinant rat GABAA receptor subtypes by $Zn^{2+}$, Neuron 5(6) (1990) 781-8.
729 [41] C. Notredame, D.G. Higgins, J. Heringa, T-Coffee: A novel method for fast and accurate
730 multiple sequence alignment, J Mol Biol 302(1) (2000) 205-17.
731 [42] A. Sali, T.L. Blundell, Comparative protein modelling by satisfaction of spatial restraints, J
732 Mol Biol 234(3) (1993) 779-815.
733 [43] G.G. Krivov, M.V. Shapovalov, R.L. Dunbrack, Jr., Improved prediction of protein side-chain
734 conformations with SCWRL4, Proteins 77(4) (2009) 778-95.
735 [44] B.R. Brooks, C.L. Brooks, 3rd, A.D. Mackerell, Jr., L. Nilsson, R.J. Petrella, B. Roux, Y. Won,
736 G. Archontis, C. Bartels, S. Boresch, A. Caflisch, L. Caves, Q. Cui, A.R. Dinner, M. Feig, S.
737 Fischer, J. Gao, M. Hodoscek, W. Im, K. Kuczera, T. Lazaridis, J. Ma, V. Ovchinnikov, E. Paci,
738 R.W. Pastor, C.B. Post, J.Z. Pu, M. Schaefer, B. Tidor, R.M. Venable, H.L. Woodcock, X. Wu, W.
739 Yang, D.M. York, M. Karplus, CHARMM: the biomolecular simulation program, J Comput Chem
740 30(10) (2009) 1545-614.
741 [45] J. Henin, R. Salari, S. Murlidaran, G. Brannigan, A predicted binding site for cholesterol on the
742 GABAA receptor, Biophys J 106(9) (2014) 1938-49.
743 [46] O. Trott, A.J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new
744 scoring function, efficient optimization, and multithreading, J Comput Chem 31(2) (2010) 455-61.
745 [47] R.R. Ugale, A.N. Sharma, D.M. Kokare, K. Hirani, N.K. Subhedar, C.T. Chopde, Neurosteroid
746 allopregnanolone mediates anxiolytic effect of etifoxine in rats, Brain Res 1184 (2007) 193-201.

747 [48] A. Barberis, E.M. Petrini, J.W. Mozrzymas, Impact of synaptic neurotransmitter concentration
748 time course on the kinetics and pharmacological modulation of inhibitory synaptic currents, Front
749 Cell Neurosci 5 (2011) 6.
750 [49] H. You, J.L. Kozuska, I.M. Paulsen, S.M. Dunn, Benzodiazepine modulation of the rat
751 GABAA receptor alpha4beta3gamma2L subtype expressed in Xenopus oocytes,
752 Neuropharmacology 59(6) (2010) 527-33.
753 [50] Z. Nusser, W. Sieghart, P. Somogyi, Segregation of different GABAA receptors to synaptic and
754 extrasynaptic membranes of cerebellar granule cells, J Neurosci 18(5) (1998) 1693-703.
755 [51] M.A. Lomize, I.D. Pogozheva, H. Joo, H.I. Mosberg, A.L. Lomize, OPM database and PPM
756 web server: resources for positioning of proteins in membranes, Nucleic Acids Res 40(Database
757 issue) (2012) D370-6.
758 [52] C. Bouillot, F. Bonnefoi, F. Liger, L. Zimmer, A microPET comparison of the effects of
759 etifoxine and diazepam on [(11)C]flumazenil uptake in rat brains, Neurosci Lett 612 (2016) 74-9.
760 [53] P.L. Toutain, A. Bousquet-Melou, Free drug fraction vs free drug concentration: a matter of
761 frequent confusion, J Vet Pharmacol Ther 25(6) (2002) 460-3.
762 [54] T.S. Maurer, D.B. Debartolo, D.A. Tess, D.O. Scott, Relationship between exposure and
763 nonspecific binding of thirty-three central nervous system drugs in mice, Drug Metab Dispos 33(1)
764 (2005) 175-81.
765 [55] S.G. Summerfield, K. Read, D.J. Begley, T. Obradovic, I.J. Hidalgo, S. Coggon, A.V. Lewis,
766 R.A. Porter, P. Jeffrey, Central nervous system drug disposition: the relationship between in situ
767 brain permeability and brain free fraction, J Pharmacol Exp Ther 322(1) (2007) 205-13.
768 [56] A. Lippa, P. Czobor, J. Stark, B. Beer, E. Kostakis, M. Gravielle, S. Bandyopadhyay, S.J.
769 Russek, T.T. Gibbs, D.H. Farb, P. Skolnick, Selective anxiolysis produced by ocinaplon, a
770 GABA(A) receptor modulator, Proc Natl Acad Sci U S A 102(20) (2005) 7380-5.
771 [57] M. Verleye, J.M. Gillardin, Effects of etifoxine on stress-induced hyperthermia, freezing
772 behavior and colonic motor activation in rats, Physiol Behav 82(5) (2004) 891-7.
773 [58] R.D. Porsolt, A. Lenegre, I. Avril, G. Doumont, Antagonism by exifone, a new cognitive
774 enhancing agent, of the amnesias induced by four benzodiazepines in mice, Psychopharmacology
775 (Berl) 95(3) (1988) 291-7.
776 [59] J. Micallef, C. Soubrouillard, F. Guet, M.E. Le Guern, C. Alquier, B. Bruguerolle, O. Blin, A
777 double blind parallel group placebo controlled comparison of sedative and mnesic effects of
778 etifoxine and lorazepam in healthy subjects [corrected], Fundam Clin Pharmacol 15(3) (2001) 209-
779 16.

780 [60] D. Deplanque, F. Machuron, N. Waucquier, E. Jozefowicz, S. Duhem, S. Somers, O. Colin, A.
781 Duhamel, R. Bordet, Etifoxine impairs neither alertness nor cognitive functions of the elderly: A
782 randomized, double-blind, placebo-controlled crossover study, Eur Neuropsychopharmacol 28(8)
783 (2018) 925-932.
784 [61] L. Wolf, A. Bauer, D. Melchner, H. Hallof-Buestrich, P. Stoertebecker, E. Haen, M. Kreutz, N.
785 Sarubin, V.M. Milenkovic, C.H. Wetzel, R. Rupprecht, C. Nothdurfter, Enhancing neurosteroid
786 synthesis--relationship to the pharmacology of translocator protein (18 kDa) (TSPO) ligands and
787 benzodiazepines, Pharmacopsychiatry 48(2) (2015) 72-7.
788 [62] D. Belelli, A. Casula, A. Ling, J.J. Lambert, The influence of subunit composition on the
789 interaction of neurosteroids with GABA(A) receptors, Neuropharmacology 43(4) (2002) 651-61.
790 [63] M.C. Gravielle, Activation-induced regulation of GABAA receptors: Is there a link with the
791 molecular basis of benzodiazepine tolerance?, Pharmacol Res 109 (2016) 92-100.
792 [64] J.R. Atack, K.A. Wafford, S.J. Tye, S.M. Cook, B. Sohal, A. Pike, C. Sur, D. Melillo, L.
793 Bristow, F. Bromidge, I. Ragan, J. Kerby, L. Street, R. Carling, J.L. Castro, P. Whiting, G.R.
794 Dawson, R.M. McKernan, TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-
795 ylmethoxy)-3-(2-fluorophenyl )-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2-
796 and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates, J
797 Pharmacol Exp Ther 316(1) (2006) 410-22.
798 [65] E.P. Christian, D.H. Snyder, W. Song, D.A. Gurley, J. Smolka, D.L. Maier, M. Ding, F.
799 Gharahdaghi, X.F. Liu, M. Chopra, M. Ribadeneira, M.J. Chapdelaine, A. Dudley, J.L. Arriza, C.
800 Maciag, M.C. Quirk, J.J. Doherty, EEG-beta/gamma spectral power elevation in rat: a translatable
801 biomarker elicited by GABA(Aalpha2/3)-positive allosteric modulators at nonsedating anxiolytic
802 doses, J Neurophysiol 113(1) (2015) 116-31.
803 [66] B.D. Fischer, J.R. Atack, D.M. Platt, D.S. Reynolds, G.R. Dawson, J.K. Rowlett, Contribution
804 of GABA(A) receptors containing alpha3 subunits to the therapeutic-related and side effects of
805 benzodiazepine-type drugs in monkeys, Psychopharmacology (Berl) 215(2) (2011) 311-9.
806 [67] A.G. de Lucas, P.K. Ahring, J.S. Larsen, I. Rivera-Arconada, J.A. Lopez-Garcia, N.R. Mirza,
807 G. Munro, GABAA alpha5 subunit-containing receptors do not contribute to reversal of
808 inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the
809 GABAA receptor allosteric modulator NS16085, Biochem Pharmacol 93(3) (2015) 370-9.
810 [68] J. Simon, H. Wakimoto, N. Fujita, M. Lalande, E.A. Barnard, Analysis of the set of GABA(A)
811 receptor genes in the human genome, J Biol Chem 279(40) (2004) 41422-35.
812 [69] S. Zhu, C.M. Noviello, J. Teng, R.M. Walsh, Jr., J.J. Kim, R.E. Hibbs, Structure of a human
813 synaptic GABAA receptor, Nature 559(7712) (2018) 67-72.